Weight loss jab Mounjaro linked to lower dementia risk
People with type 2 diabetes and obesity who are taking the drugs are also less likely to die prematurely, researchers found.
The study saw experts from Taiwan examine date on 60,000 people from around the world, with an average age of 58, who had type 2 diabetes and obesity.
Key differences between three weight-loss injections: Mounjaro, Wegovy, and Ozempic. https://t.co/WhHodrztS1 pic.twitter.com/Rll5Eg3ycU — Paul Wischmeyer MD (@Paul_Wischmeyer) July 4, 2025
Around half were given GLP agonist drugs semaglutide and tirzepatide – which are sold under the brand names Wegovy and Mounjaro. Semaglutide is also the main ingredient for the type 2 diabetes drug Ozempic.
GLP agonists can reduce a person's appetite; slow down their digestion; reduce the amount of sugar the liver makes and they help the body to make more insulin when needed.
The other half used other anti-diabetic medication.
📢Important update
Eligible people in #Dorset will be able to access Tirzepatide (Mounjaro) weight management medication from autumn 2025.
✅Around 1,000 people in Dorset will qualify under strict national criteria
✅No need to contact your doctor
More: https://t.co/ml4QJgZ224 pic.twitter.com/uURpuIuYzx — NHS Dorset (@NHSDorset) June 23, 2025
During a seven-year follow-up period, researchers found that people given the GLP agonist drugs appeared to have a 37% lower risk of dementia and a 19% reduced risk of stroke.
They were also 30% less likely to die during the follow-up period.
And when researchers looked at the data further they found even greater benefits in people aged 60 or older, women, and those with a body mass index score of 30 to 40.
They found no differences in Parkinson's disease or brain bleeds.
The academics said their findings suggest 'potential neuroprotective and cerebrovascular benefits' of the drugs but they called for more studies to confirm the findings.
Recommended reading:
'These findings suggest that semaglutide and tirzepatide may offer neuroprotective and cerebrovascular benefits beyond glycemic control, potentially improving long-term cognitive and survival outcomes in adults with type 2 diabetes and obesity,' they wrote in the journal JAMA Network Open.
Commenting on the study, Professor Tara Spires-Jones, director of the Centre for Discovery Brain Sciences at the University of Edinburgh and group leader in the UK Dementia Research Institute, said: 'This is a very interesting study adding to evidence that GLP1 receptor agonists are associated with a lower risk of dementia in people with type 2 diabetes and obesity.
'This type of study cannot determine whether the drugs reduced disease risk by directly protecting the brain.
'It is highly likely that effectively treating type 2 diabetes and obesity would reduce dementia and stroke risk as they are known risk factors for these conditions.
'Further work is needed including randomised clinical trials to confirm these drugs are protective in people with diabetes and obesity and other trials are needed to determine whether these drugs will be protective in people who do not have type 2 diabetes and obesity.'
Recommended reading:
Dr Richard Oakley, associate director of research and innovation at Alzheimer's Society, said: 'It is well established that diabetes and obesity can increase your risk of developing dementia.
'This study supports existing evidence that shows these drugs may reduce dementia risk, particularly for people aged 60 and over who are living with type 2 diabetes and obesity.
'Although interesting, we can't draw conclusions from this study alone as it is an observational study, only a small number of people who took part went on to develop dementia and as the impact of these drugs on different types of dementia is not clear.
'There are clinical trials currently looking at whether drugs like these can be used to treat early-stage Alzheimer's disease, so this is a really exciting area being explored in the research fight against dementia.'
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
NBC News
2 hours ago
- NBC News
GLP-1 weight loss drug use among kids surges
After the American Academy of Pediatrics recommended the use of certain GLP-1 weight loss drugs in January of 2023, the use among children skyrocketed by 65% immediately and has continued to grow since. NBC News' Kate Snow has more on what age experts say these drugs can be used by children.
Reuters
3 hours ago
- Reuters
Hims & Hers hit with investor lawsuits after Novo ends Wegovy partnership
July 15 (Reuters) - Telehealth company Hims & Hers (HIMS.N), opens new tab is facing a growing number of U.S. investor lawsuits after Novo Nordisk's ( opens new tab decision last month to end a short-lived partnership to sell its Wegovy weight-loss drug through the platform sent shares plunging. A group of shareholders sued Hims on Monday in federal court in San Francisco, accusing its board and senior executives of making false and misleading statements about its financial condition and operations. The case was filed as a so-called derivative lawsuit on behalf of the company. The lawsuit follows two securities class actions filed by Hims investors in the same court last month, seeking damages over the drop in stock price after Novo in late June ended what the companies had initially described as a long-term collaboration designed to make obesity care and treatment more affordable and accessible. Hims, Novo and the lawyers who filed Monday's lawsuit did not immediately respond to requests for comment. Danish drugmaker Novo is not a defendant in the lawsuits. Founded in 2017, San Francisco-based Hims provides health and wellness products focused on weight loss, sexual and mental health and hair loss. Novo on June 23 said it was ending their partnership that began in late April, citing Hims' alleged improper marketing and sales of Wegovy copies. Novo accused Hims of 'deceptive promotion and selling of illegitimate, knockoff versions of Wegovy that put patient safety at risk.' Hims CEO Andrew Dudum responded, opens new tab in a post on X that day that accused Novo management of misleading the public and making anticompetitive demands 'that infringe on the independent decision making of providers and limit patient choice.' Hims shares fell $22.24, or over 34%, after Novo's announcement, declining from $64.22 per share on June 20 to close at $41.98 per share on June 23. The stock closed on Monday at $52.03 a share. The tight supply of Wegovy in the United States had allowed Hims and others to sell cheaper, compounded versions of the drug, known chemically as semaglutide. The U.S. Food and Drug Administration in February removed Wegovy from the agency's shortage list. Hims said the decision meant it could not guarantee continued sales of compounded semaglutide. The case is Steve Jones v. Andrew Dudum, U.S. District Court, Northern District of California, No. 3:25-cv-05866-AGT. For plaintiff: Shane Rowley of Rowley Law PLLC, and Francis "Casey" Flynn Jr. of Law Office of Francis J. Flynn Jr For defendants: No appearances yet Read more: Novo, Hims & Hers engage in war of words after Wegovy deal falls apart US judge upholds FDA's removal of Ozempic, Wegovy from drug shortage list Novo Nordisk to sell Wegovy through telehealth firms to cash-paying US customers
The Independent
8 hours ago
- The Independent
How weight-loss jabs could help lower dementia risk
New research indicates that weight-loss injections, including popular drugs like Wegovy and Mounjaro, may offer protection against serious conditions such as dementia and stroke. The study also suggests that individuals with type 2 diabetes and obesity prescribed these medications could face a reduced risk of premature death. Experts from Taiwan conducted a comprehensive study, examining data from 60,000 people worldwide with an average age of 58, all diagnosed with type 2 diabetes and obesity. During a seven-year follow-up, participants given GLP agonist drugs showed a 37 per cent lower risk of dementia, a 19 per cent reduced risk of stroke, and were 30 per cent less likely to die. Academics noted potential neuroprotective and cerebrovascular benefits but called for more studies, including randomised clinical trials, to confirm these findings.
